Compounds > sorafenib
Page last updated: 2024-09-05

sorafenib and semaxinib

sorafenib has been researched along with semaxinib in 4 studies

Compound Research Comparison

Studies
(sorafenib)		Trials
(sorafenib)		Recent Studies (post-2010)
(sorafenib)		Studies
(semaxinib)		Trials
(semaxinib)		Recent Studies (post-2010) (semaxinib)
6,5207305,25148031218

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)semaxinib (IC50)
Chain A, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RETHomo sapiens (human)0.17
Chain A, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RETHomo sapiens (human)0.17
Chain A, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RETHomo sapiens (human)0.17
Dihydrofolate reductaseHomo sapiens (human)2.4
Dihydrofolate reductaseMus musculus (house mouse)2.4
Epidermal growth factor receptorHomo sapiens (human)3.592
Platelet-derived growth factor receptor betaMus musculus (house mouse)4.05
Macrophage colony-stimulating factor 1 receptorHomo sapiens (human)0.084
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)0.17
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)0.5
Platelet-derived growth factor receptor betaHomo sapiens (human)2.3563
Mast/stem cell growth factor receptor KitHomo sapiens (human)0.365
Fibroblast growth factor receptor 1Homo sapiens (human)4.865
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)0.5
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)3.89
Dihydrofolate reductasePneumocystis carinii2.4
Platelet-derived growth factor receptor alphaHomo sapiens (human)0.2
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.7648
Fibroblast growth factor receptor 2Homo sapiens (human)5
Fibroblast growth factor receptor 4Homo sapiens (human)5
Fibroblast growth factor receptor 3Homo sapiens (human)5
Platelet-derived growth factor receptor alpha Mus musculus (house mouse)4.05
Vascular endothelial growth factor receptor 3Homo sapiens (human)0.275
Vascular endothelial growth factor receptor 2Mus musculus (house mouse)1.04
Vascular endothelial growth factor receptor 2Homo sapiens (human)1.0999
Vascular endothelial growth factor receptor 1Mus musculus (house mouse)1.04
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.16
Mu-type opioid receptorCavia porcellus (domestic guinea pig)0.2
Vascular endothelial growth factor receptor 2Danio rerio (zebrafish)0.068
1,25-dihydroxyvitamin D-3 receptor Sus scrofa domesticus (domestic pig)1.04
Dihydrofolate reductaseRattus norvegicus (Norway rat)2.4
ALK tyrosine kinase receptorHomo sapiens (human)1.505

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Anderson, KC; Podar, K1
Fiedler, W; Wellbrock, J1
Hayashi, T; Ijiri, Y; Imano, H; Kato, R1

Reviews

2 review(s) available for sorafenib and semaxinib

ArticleYear
Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
    Current cancer drug targets, 2011, Volume: 11, Issue:9

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Hematologic Neoplasms; Humans; Indoles; Multiple Myeloma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A; Wnt Signaling Pathway

2011
Clinical experience with antiangiogenic therapy in leukemia.
    Current cancer drug targets, 2011, Volume: 11, Issue:9

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Humans; Indoles; Lenalidomide; Leukemia; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib; Thalidomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2011

Other Studies

2 other study(ies) available for sorafenib and semaxinib

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Activation of inflammasomes by tyrosine kinase inhibitors of vascular endothelial growth factor receptor: Implications for VEGFR TKIs-induced immune related adverse events.
    Toxicology in vitro : an international journal published in association with BIBRA, 2021, Volume: 71

    Topics: Antineoplastic Agents; Axitinib; Caspases; HMGB1 Protein; Humans; Indazoles; Indoles; Inflammasomes; Interleukin-1beta; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; THP-1 Cells

2021